Our purpose

Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies.

Our credentials

Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team.

To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing.

Listing on the SIX Swiss Exchange under the symbol KURN since 2016
A commercial & research footprint that spans >20 markets
4 teams of internationally renowned clinical and scientific expert advisers
>25 orthobiologics-related patents
>400 patients evaluated in Level I, randomized controlled clinical trials
>20 well-controlled Level I-IV clinical trials initiated, including 6 that are complete¹
Published Level I evidence published in Spine

Map with Australia, Austria, Brazil, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Lebanon, Liechtenstein, Luxembourg, Malta, Netherlands, New Zealand, Norway, Portugal, Qatar, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, and the United States highlighted

Conferences

Meet the Kuros team at our next conference and discover how our groundbreaking technology is transforming the future of bone healing. Don’t miss this chance to connect, learn, and be inspired!

22 Oct 2025

Eurospine

Copenhagen, Denmark

14 Nov 2025

North American Spine Society (NASS)

Denver, CO

23 Nov 2025

Spine IEP

Location TBD

03 Dec 2025

Cervical Spine Research Society (CSRS)

Washington, DC

Our Story

January 2025

Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division

November 2024

Kuros Biosciences expands into extremities markets

October 2024

PRECISE Level 1 clinical trial sites activated, Launch of MagnetOs in Middle East countries

June 2024

MagnetOs Level 1 study published in Spine, MagnetOs Easypack Putty FDA cleared for standalone, extremities and pelvis

April 2024

MagnetOs Putty FDA cleared for interbody use

January 2024

MagnetOs Easypack Putty and MagnetOs Granules FDA cleared for interbody use, MagnetOs Putty FDA cleared for standalone use

November 2023

MagnetOs Flex Matrix FDA cleared for interbody use

October 2023

Chris Fair appointed CEO

August 2023

Sales distribution agreement with top 3 spine company announced

June 2023

US HQ moved to Atlanta

MagnetOs Flex Matrix bone graft with bone marrow aspirate

October 2022

Full commercial launch of MagnetOs Flex Matrix (US)

MagnetOs Easypack Putty bone graft coming out of a syringe

June 2022

Full commercial launch of MagnetOs Easypack Putty (US)

February 2022

MagnetOs Granules FDA cleared for standalone use

August 2021

US office opened in Boston

July 2021

First human data for MagnetOs published

July 2021

Launch of MagnetOs in nine European countries

September 2019

Full commercial launch of MagnetOs Granules and MagnetOs Putty (US)

July 2019

Signing of first APAC distributor

June 2018

First patient treated with MagnetOs (US)

February 2018

US Registration and virtual office established

May 2017

First patient treated with MagnetOs (EU)

January 2017

Acquired Xpand Biotechnology in 2017
to strengthen the biologics platform

May 2016

Listed on Swiss Exchange

March 2000

Founded as a spin-off of Swiss Federal Institute of Technology in Zurich

Ready to make an impact in a dynamic, international environment?

Explore our open positions and join Kuros Biosciences today!

Explore Careers

References and Disclaimers

Nothing to display.

Wright, et al. J Bone Joint Surg Am. 2005;87(9):1909-1910.

MAT-0226